Growing Demand for Personalized Medicine
Personalized medicine, where tailored therapy is made available to patients with an understanding of the molecular basis of diseases, has become popular over the recent years. Genetic testing and genome sequencing are two of the most important tools that are used to understand the molecular basis of a disease. European countries are screened for several genetic diseases, as an early detection of these diseases can prevent the onset of symptoms, or minimize the severity of the disease. Genetic testing for cancer diagnosis can indicate the predisposition of the disease in the gene, before its actual manifestation. This type of diagnostic technique enables a person to take precautionary steps, and avoid possible risks in the future.
Social and Ethical Implications of Genetic Testing
Insurance is an important asset to people. The fear of discrimination by insurance companies discourages people from undertaking genetic tests, which is a restraining factor for the market growth. The expensive nature of genetic tests affects the market, adversely. At times, the payments made by individuals are not reimbursed through insurance, thus, affecting the pockets of these patients. The high-import duty by the government on genetic tests kits also acts as a barrier to the market growth.
North America to Dominate the Market
The genetic testing market is segmented by treatment type, diseases, technology, and geography. By geography, the market has been segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America.
Owing to the presence of well-established healthcare facilities and new discoveries in the field of genetic markers, North America dominates the genetic testing market. The Asia-Pacific market is expected to register the highest CAGR, as government and private firms are making significant investments in the healthcare industry. Over the last couple of years, to invest in the Japanese market, several mergers, acquisitions, and collaborations between companies have taken place.
Key Developments in the Market
- September 2017: Myriad Launched riskScore to enhance the hereditary cancer test myRisk. riskScore determines the risk of women to get breast cancer by analyzing their genome.
- July 2017: Admera Health Partners collaborates with Helix to Launch Genetic Tests to Assess the Risk of Inherited High Cholesterol, Sudden Cardiac Death, and Inherited Diabetes
Reasons to Purchase this Report
- Market analysis for the Global Genetic testing Market, with region-specific assessments and competition analysis on the global and regional scale
- Analyzing various market perspectives, with the help of Porter’s five forces analysis
- The treatment type that is expected to dominate the market
- Regions that are expected to witness fastest growth during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- 3 months analyst support, along with the Market Estimate sheet (in excel)
This report can be customized to meet your requirements..
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product And Services
5.2.5 Competitive Rivalry Within the Industry
6. Drivers, Restraints, Opportunities And Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Emphasis on Early Disease Detection and Prevention
6.1.2 Growing Demand for Personalized Medicine
6.1.3 Increasing Application of Genetic Testing in Oncology
6.2 Market Restraints
6.2.1 High Costs of Genetic Testing
6.2.2 Social and Ethical Implications of Genetic Testing
6.4 Key Challenges
7. Market Segmentation
7.1 Segmentation-By Type
7.1.1 Carrier Testing
7.1.2 Diagnostic Testing
7.1.3 Newborn Screening
7.1.4 Predictive and Presymptomatic Testing
7.1.5 Prenatal Testing
7.1.6 Nutrigenomic Testing
7.2 Segmentation-By Disease
7.2.1 Alzheimer’s Diseases
7.2.3 Cystic Fibrosis
7.2.4 Sickle Cell Anemia
7.2.5 Duchenne Muscular Dystrophy
7.2.7 Huntington’s Disease
7.2.8 Special Diseases
7.3 Segmentation-By Technology
7.3.1 Cytogenetic Testing
7.3.2 Biochemical Testing
7.3.3 Molecular Testing
7.4 Segmentation-By Geography
7.4.1 North America
184.108.40.206 Rest Of Europe (RoE)
220.127.116.11 Australia & New Zealand
18.104.22.168 South Korea
22.214.171.124 Rest Of Asia-Pacific
7.4.4 Middle East & Africa
126.96.36.199 South Africa
188.8.131.52 Rest Of the Middle East & Africa
7.4.5 South America
184.108.40.206 Rest Of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 23 and Me Inc.
9.2 Abbott Molecular Inc.
9.3 Ariosa Diagnostics Inc.
9.4 Biocartis SA
9.6 Illumina Inc.
9.7 Luminex Corporation
9.8 Sequenom Inc.
9.9 Myriad Genetics
9.10 Transgenomic Inc.
10. Future of the Market